21,423 Shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) Bought by Concorde Asset Management LLC

Concorde Asset Management LLC purchased a new position in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,423 shares of the company’s stock, valued at approximately $858,000. Concorde Asset Management LLC owned about 0.10% of Fulgent Genetics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC increased its position in Fulgent Genetics by 3.5% in the first quarter. Geode Capital Management LLC now owns 97,106 shares of the company’s stock worth $1,044,000 after purchasing an additional 3,313 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of Fulgent Genetics during the second quarter valued at $461,000. Paloma Partners Management Co purchased a new stake in shares of Fulgent Genetics during the first quarter valued at $121,000. Russell Investments Group Ltd. boosted its stake in shares of Fulgent Genetics by 67.5% during the second quarter. Russell Investments Group Ltd. now owns 477,823 shares of the company’s stock valued at $7,641,000 after purchasing an additional 192,544 shares during the period. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Fulgent Genetics by 328.2% during the second quarter. Advisor Group Holdings Inc. now owns 8,525 shares of the company’s stock valued at $137,000 after purchasing an additional 6,534 shares during the period. Institutional investors own 61.08% of the company’s stock.

In other news, COO Jian Xie sold 1,976 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $27.86, for a total transaction of $55,051.36. Following the transaction, the chief operating officer now owns 603,712 shares in the company, valued at $16,819,416.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Hanlin Gao sold 1,308 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.11, for a total transaction of $53,771.88. Following the transaction, the insider now owns 1,281,351 shares in the company, valued at approximately $52,676,339.61. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 257,339 shares of company stock worth $10,741,514. Corporate insiders own 45.00% of the company’s stock.

Fulgent Genetics stock traded down $1.24 during trading hours on Monday, reaching $34.61. The stock had a trading volume of 12,399 shares, compared to its average volume of 582,131. The company has a market cap of $792.82 million, a price-to-earnings ratio of 298.77 and a beta of 1.68. The business’s 50 day moving average price is $36.54 and its 200-day moving average price is $25.18. Fulgent Genetics, Inc. has a 52 week low of $6.70 and a 52 week high of $52.47.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.16. Fulgent Genetics had a net margin of 5.78% and a return on equity of 5.05%. The firm had revenue of $17.27 million for the quarter, compared to the consensus estimate of $14.52 million. On average, equities analysts anticipate that Fulgent Genetics, Inc. will post 1.07 earnings per share for the current fiscal year.

A number of research firms recently weighed in on FLGT. BidaskClub lowered shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research note on Monday, October 19th. CSFB upped their price objective on shares of Fulgent Genetics from $13.00 to $42.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th. Zacks Investment Research lowered shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research note on Monday, October 19th. Piper Sandler upped their price objective on shares of Fulgent Genetics from $68.00 to $73.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Finally, Credit Suisse Group upped their price objective on shares of Fulgent Genetics from $13.00 to $42.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Fulgent Genetics currently has a consensus rating of “Hold” and a consensus target price of $45.33.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes.

Recommended Story: What do I need to know about analyst ratings?

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.